Lorna Meldrum

Lorna joined the CSL Group in 2013. She was appointed to the role of VP, Pandemic Response Solutions late in 2019 before extending her commercial responsibility to include the International markets outside of North America. She was previously VP, Commercial Operations Asia Pacific where she was instrumental in enhancing the CSL Seqirus presence across the Asia Pacific region. Lorna has enjoyed a successful career in the pharmaceutical industry, encompassing clinical research, business development, marketing and sales, across a wide variety of therapeutic areas.  She immigrated to Australia in 2002 and prior to bio CSL / CSL Seqirus, held roles at GSK and Ikaria Australia Pty Ltd. Lorna graduated with a PhD in Neurobiology (University College London); BSc in Pharmacology (University of Glasgow) and went on to hold academic positions at the Cardiothoracic Institute at the Royal Brompton Hospital (London) and at the Royal Post Graduate Medical School (London).